N/A N=10 Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
Phase 3 N=1,923 A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
SARS-CoV-2 Infection
Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years
Phase 4 N=60 The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients
COVID-19
Primary: E Genes — 28.50; 27.33; 30.28; 27.80 Cycle
N/A N=143 HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
COVID
Primary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=215 COVID-19 Risk Reduction Among African American Parishioners
Coronavirus
Primary: Mean Change in the Ability to Implement COVID-19 Health Guidelines Among African American Churches in South Los Angeles 3 Months After Workshop — 3.00000 score on a…
Phase 2 N=32 COVID Protection After Transplant-Immunosuppression Reduction
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
N/A N=571 Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers
SARS-CoV-2
Primary: Number of Participant Health Care Workers With a Positive Rapid, At-home, Point-of-care (POC) SARS-CoV2 IgG Antibody Test. — 8 Participants
Phase 2 N=217 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
Phase 4 N=659 BCG Vaccine for Health Care Workers as Defense Against COVID 19
Coronavirus · Coronavirus Infection · Coronavirus as the Cause of Diseases Classified Elsewhere
Primary: Number of New COVID 19 Infections — 25; 21 Participants
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
Phase 3 N=1,676 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Covid19 · Non-specific Effects of Vaccines · Heterologous Immunity
Primary: Acute Infection — 424; 469; 212; 236 Events — p=< 0.05
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
N/A N=1,076 Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
SARS-CoV-2 · Serology · Students
Primary: Frequency of Handwashing — 412; 432; 65; 75 Participants
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
N/A N=12 Aerosol Particle Concentrations Among Different Oxygen Devices for Spontaneous Breathing Patients With Tracheostomy
Transmission, Patient-Professional
Primary: Aerosol Particle Concentrations With Size of 1-3 Micrometer at 1 Foot Away From the Patient — 13000; 11000; 10000; 12000 particles/m3
N/A N=88 Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
COVID 19
Primary: Change in Viral Load in the Nasopharynx Over the Course of COVID-19 Infection — .116; .071; .118 Log10 copies/mL/days
Phase 2 N=98 COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
COVID-19 · SARS-CoV 2
Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
Phase 2 N=48 Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
Covid19
Primary: Recruitment Feasibility — 46 Participants
N/A N=526 Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
Sars-CoV2 · Serum; Disease
Primary: Rate of Positive Serological Immune Status to a Previous Infection by the SARS-CoV-2 Virus at Inclusion — 18 Participants
N/A N=300 Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Androgenetic Alopecia · Coronavirus Disease 2019 · Covid19
Primary: Androgenetic Alopecia Frequency in Participants. — 209; 37; 11; 43 Participants
N/A N=300 Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
SARS-CoV 2 · COVID-19
Primary: Number of Participants With COVID-19 Antibodies — 8; 284 Participants — p=>0.18
N/A N=230 The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners
Covid19
Primary: Number of Participants Screened (Molecular) — 169; 61 Participants
Phase 1 N=14 Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
SARS-CoV-2 Infection
Primary: Safety of Treatment With High-titer Anti-SARS-CoV-2 Plasma as Assessed by Adverse Events — 0 Participants
N/A N=20 Novel Mucosal Correlates Of RSV Protection In Older Adults
Respiratory Tract Infections
Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events